[Skip to Content]
[Skip to Content Landing]
Article
April 1990

Iofetamine I 123 Single Photon Emission Computed Tomography Is Accurate in the Diagnosis of Alzheimer's Disease

Author Affiliations

From the Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston (Drs Johnson, Holman, and Nagel and Mr English); Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (Drs Johnson, Rosen, and Growdon); and Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge (Dr Rosen).

Arch Intern Med. 1990;150(4):752-756. doi:10.1001/archinte.1990.00390160030007
Abstract

• To determine the diagnostic accuracy of iofetamine hydrochloride I 123 (IMP) with single photon emission computed tomography in Alzheimer's disease, we studied 58 patients with AD and 15 age-matched healthy control subjects. We used a qualitative method to assess regional IMP uptake in the entire brain and to rate image data sets as normal or abnormal without knowledge of subjects' clinical classification. The sensitivity and specificity of IMP with single photon emission computed tomography in AD were 88% and 87%, respectively. In 15 patients with mild cognitive deficits (Blessed Dementia Scale score, ≤ 10), sensitivity was 80%. With the use of a serniquantitative measure of regional cortical IMP uptake, the parietal lobes were the most functionally impaired in AD and the most strongly associated with the patients' Blessed Dementia Scale scores. These results indicated that IMP with single photon emission computed tomography may be a useful adjunct in the clinical diagnosis of AD in early, mild disease.

(Arch Intern Med. 1990;150:752-756)

×